CervoMed Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CervoMed Inc. (CRVO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.31% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-07
- CervoMed Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 1.70%.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-03-31 was 2.30%, a 9.52% increase year-over-year.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-03-31 was 2.10%.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2015 was 1.84%.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2013 was 0.35%.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2011 was 0.83%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.31% 10-Q · filed 2026-08-07 | |||
| 2025-06-30 | 4.35% 10-Q · filed 2026-08-07 | |||
| 2020-09-30 | 0.90% 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 1.30% 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | 1.70% 10-Q · filed 2020-05-11 | |||
| 2019-09-30 | 2.20% 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | 2.20% 10-Q · filed 2019-08-08 | |||
| 2018-09-30 | 2.40% 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | 2.40% 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | 2.30% 10-Q · filed 2018-05-10 | |||
| 2017-09-30 | 2.00% 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | 2.00% 10-Q · filed 2018-08-10 | |||
| 2017-03-31 | 2.10% 10-Q · filed 2017-05-15 | |||
| 2016-06-30 | 1.40% 10-Q · filed 2016-08-15 | |||
| 2015-12-31 | 1.84% 10-K · filed 2016-03-25 | |||
| 2013-12-31 | 0.35% 10-K · filed 2015-04-03 | |||
| 2012-06-30 | 0.69% 10-Q/A · filed 2012-09-07 | |||
| 2011-12-31 | 0.83% 10-K/A · filed 2013-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |